In line with our mission to enhance extra corporal albumin dialysis to the next stage we started our research & development project on a new set-up combining optimized flow dynamics and refined components. Funded by grants in pre-seed we initiated fundraising and completed seed phase financing in 2008. Successful feasibility studies resulted in the Hepalbin®-Adsorbent, which easily removed unwanted stabilizers from human albumin solutions to enhance albumin binding capacity significantly.

Based on promising in vitro data, we continued to evolve our technology. Testing a variety of prototypes our efforts paid off - We improved the nano structured Hepalbin®-Adsorbent for bed-side removal of contaminations and to prepare large albumin pools for albumin dialysis. 
The new CE certified infusion device became the worldwide first technology for applying human albumin solutions without caprylate and acetyltryptophanate, which is most important for patients with liver failure. Achieving this fundamental milestone enabled Albutec to complete Series A financing to proceed to the next stage in albumin dialysis.

After launching the CE marked Hepalbin®-Cluster12 for albumin dialysis in 2013 we initiated a clinical trial to validate and compare performance data. Demonstrating superiority and significance in survival and recovery led to thousands of successful treatments. Motivated by these results exceeding our expectations we constantly enhanced our technology introducing the all-new modular Hepalbin MaxiCycler to the market in Q4 2021. Based on that latest innovation we are preparing our Series B financing in early 2022 to receive the next steps in our roll-out strategy for Europe and the US.